[en] We provide updated guidance and standards for the indication, acquisition, and interpretation of [18F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [18F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [18F]FDG PET/CT imaging in routine practice and future research.
Deroose, Christophe M; Nuclear Medicine, University Hospitals (UZ) Leuven, 3000, Leuven, Belgium ; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
Balogova, Sona; Nuclear Medicine, Comenius University, Bratislava, Slovakia ; Médecine Nucléaire, Hôpital Tenon, GH AP.SU, Paris, France
Lapa, Constantin; Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany
Withofs, Nadia ; Université de Liège - ULiège > Département des sciences cliniques
Subesinghe, Manil; Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
Jamet, Bastien; Médecine Nucléaire, CHU Nantes, F-44000, Nantes, France
Zamagni, Elena ; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. e.zamagni@unibo.it ; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. e.zamagni@unibo.it
Ippolito, Davide; Department of Diagnostic Radiology, Fondazione IRCCS San Gerardo dei Tintori, Via Pergolesi 33, 20900, Monza, Italy ; University of Milano-Bicocca, School of Medicine, Via Cadore 33, 20090, Monza, Italy
Delforge, Michel; University Hospitals (UZ) Leuven, 3000, Leuven, Belgium
Open access funding provided by Alma Mater Studiorum - Universit\u00E0 di Bologna within the CRUI-CARE Agreement. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.CN has received consultant honoraria from Keosys and funding from Radius, Immedica, Thema Sinergie. CMD has received consultant honoraria from Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO and Immedica Pharma; his institution has received travel support from GE Healthcare, Sirtex. CL has received research funding from RayzeBio and consultant honoraria from Blue Earth Diagnostics Ltd. (BED, Oxford, UK) and Novartis. NW has received consultant honoraria from Novartis and SCK CEN. EZ has served consulting/advisory role and received honoraria from Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides, Menarini Stemline. MD has received speaker honoraria from BMS, GSK, Janssen, Sanofi, Stemline. FKB has received consultant honoraria from Novartis AAA, Telix pharmaceuticals and Immedica and research funding from Siemens.
van de Donk, Niels WCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet (Br Ed). 2021. https://doi.org/10.1016/S0140-6736(21)00135-5.
E. Zamagni S. Barbato M. Cavo How I treat high-risk multiple myeloma Blood 2022 10.1182/blood.2020008733 34727187
Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk, Niels WCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica (Roma). 2018. https://doi.org/10.3324/haematol.2018.189159.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, Leleu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, San Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 2014. https://doi.org/10.1016/S1470-2045(14)70442-5.
Greipp PR, San Miguel J, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J, Durie BGM, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Harousseau J, Kyle RA. International staging system for multiple myeloma. 2005. https://doi.org/10.1200/JCO.2005.04.242.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised international staging system for multiple myeloma: a report from international myeloma working group. 2015. https://doi.org/10.1200/JCO.2015.61.2267.
D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos M, Dall'Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. 2022. https://doi.org/10.1200/JCO.21.02614.
Durie BGM, Harousseau J, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International uniform response criteria for multiple myeloma. 2006. https://doi.org/10.1038/sj.leu.2404284.
Dimopoulos MA, Moreau P, Terpos E, Mateos M, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U. Multiple myeloma: EHA‐ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. 2021. https://doi.org/10.1097/HS9.0000000000000528.
Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B. International Myeloma Working Group recommendations for global myeloma care. 2014. https://doi.org/10.1038/leu.2013.293.
Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. 2021. https://doi.org/10.1016/S1470-2045(20)30559-3.
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos M, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk, Niels W C J, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. 2018. https://doi.org/10.1038/s41375-018-0040-1.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015. https://doi.org/10.1007/s00259-014-2961-x.
F. Stacul M. Bertolotto H.S. Thomsen G. Pozzato D. Ugolini M. Bellin G. Bongartz O. Clement G. Heinz-Peer A. van der Molen P. Reimer J.A.W. Webb Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines Eur Radiol 2018 10.1007/s00330-017-5023-5 29426991 5986826
R. Rakheja A. Ciarallo Y.Z. Alabed M. Hickeson Intravenous administration of diazepam significantly reduces brown fat activity on 18F-FDG PET/CT Am J Nucl Med Mol Imaging 2011 1 1 29 35 1:CAS:528:DC%2BC3MXhsFWitL7O 23133792 3477718
Söderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. 2007. https://doi.org/10.1007/s00259-006-0318-9.
M.G.G. Sturkenboom O.S. Hoekstra E.J. Postema J.M. Zijlstra J. Berkhof E.J.F. Franssen A randomised controlled trial assessing the effect of oral diazepam on 18F-FDG uptake in the neck and upper chest region Mol Imaging Biol 2009 10.1007/s11307-009-0207-2 19326174 2719725
O. Belohlavek M. Jaruskova [18F]FDG-PET scan in patients with fasting hyperglycemia Q J Nucl Med Mol Imaging 2016 60 4 404 12 25017897
Caobelli F, Pizzocaro C, Paghera B, Guerra UP. Proposal for an optimized protocol for intravenous administration of insulin in diabetic patients undergoing (18)F-FDG PET/CT. 2013. https://doi.org/10.1097/MNM.0b013e32835d1034.
Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, Lentzsch S, Moreau P, Cavo M, Miguel JS, Dimopoulos MA, Rajkumar SV, Durie BGM, Terpos E, Delorme S. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. 2018. https://doi.org/10.1038/s41408-018-0124-1.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. 2003. https://doi.org/10.4065/78.1.21.
Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters – van den Bos, Indra C., Heggelman BGF, Nievelstein R, Otten RHJ, Lammeren – Venema D, Zijlstra JM, Arens AIJ, Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S. Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review. 2013. https://doi.org/10.1111/bjh.12346.
Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen W, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. 2019. https://doi.org/10.1016/S1470-2045(19)30309-2.
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017. https://doi.org/10.1093/annonc/mdx096.
National Institute for Health and Care Excellence. Myeloma: diagnosis and management [NG35]. 2016. https://www.nice.org.uk/guidance/ng35. Accessed Feb 2016.
Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group 2017. https://doi.org/10.1038/bcj.2017.78.
Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, Reiser MF. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. 2008. https://doi.org/10.2214/AJR.07.2635.
Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, Østergaard B, Schlemmer H, Landgren O, Asmussen JT, Kaiser MF, Padhani A. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). 2019. https://doi.org/10.1148/radiol.2019181949.
J.C. Dutoit M.A. Vanderkerken J. Anthonissen F. Dochy K.L. Verstraete The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma Eur Radiol 2014 10.1007/s00330-014-3324-5 25106487
Bäuerle T, Hillenglass J, Goldschmidt H, Delorme S, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, Heiss C, Wagner-Gund B, Neben K, Kauczor H. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging 2009. https://doi.org/10.1148/radiol.2522081756.
Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim C, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BGM, Terpos E. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. 2015. https://doi.org/10.1200/JCO.2014.57.9961.
Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk, Niels W C J, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A. European myeloma network guidelines for the management of multiple myeloma-related complications. 2015. https://doi.org/10.3324/haematol.2014.117176.
Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos M, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. 2017. https://doi.org/10.1016/S1470-2045(17)30189-4.
Weng W, Dong M, Zhang J, Yang J, Xu Q, Zhu Y, Liu N. A systematic review of MRI, scintigraphy, FDG-PET and PET/CT for Diagnosis of multiple myeloma related bone disease - which is best? 2014. https://doi.org/10.7314/APJCP.2014.15.22.9879.
Lu Y, Chen J, Lin W, Liang J, Wang H, Tsai S, Kao C. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. 2012. https://doi.org/10.1097/RLU.0b013e31825b2071.
Walker RC, Brown TL, Jones-Jackson LB, De Blanche L, Bartel T. Imaging of multiple myeloma and related plasma cell dyscrasias. 2012. https://doi.org/10.2967/jnumed.111.098830.
S. Sager N. Ergül H. Ciftci G. Cetin S.İ. Güner T.F. Cermik The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma Skeletal Radiol 2011 10.1007/s00256-010-1088-9 21229354
Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings. 2014. https://doi.org/10.1016/j.ejrad.2014.09.012.
Kraeber-Bodéré F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin M, Minnema MC, Jamet B, Bodet-Milin C, De Keizer B, Béné MC, Avet-Loiseau H, Sonneveld P, Pei L, Rigat F, De Boer C, Vermeulen J, Kampfenkel T, Lambert J, Moreau P. Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. 2023. https://doi.org/10.3324/haematol.2021.280051.
Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. 2011. https://doi.org/10.1182/blood-2011-06-361386.
P. Moreau M. Attal D. Caillot M. Macro L. Karlin L. Garderet T. Facon L. Benboubker M. Escoffre-Barbe A. Stoppa K. Laribi C. Hulin A. Perrot G. Marit J. Eveillard F. Caillon C. Bodet-Milin B. Pegourie V. Dorvaux C. Chaleteix K. Anderson P. Richardson N.C. Munshi H. Avet-Loiseau A. Gaultier J. Nguyen B. Dupas E. Frampas F. Kraeber-Bodere Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study J Clin Oncol 2017 35 25 2911 2918 1:CAS:528:DC%2BC1cXitVemtrzM 10.1200/JCO.2017.72.2975 28686535 5578392
Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-017-3909-8.
Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma. 2017. https://doi.org/10.1182/blood-2017-03-774422.
Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. 2017. https://doi.org/10.1038/s41467-017-00296-y.
Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. 2018. https://doi.org/10.1182/blood-2018-04-842880.
Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, Poos AM, Zangari M, Thanendrarajan S, Davies FE, Walker BA, Barlogie B, Landgren O, Morgan GJ, van Rhee F, Weinhold N. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. 2022. https://doi.org/10.1038/s41467-022-32145-y.
Alberge J, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Béné M, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. Molecular signature of 18F-FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study. 2022. https://doi.org/10.2967/jnumed.121.262884.
Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 2007. https://doi.org/10.3324/haematol.10554.
Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. 2015. https://doi.org/10.1097/RLU.0000000000000696.
O. Westerland A. Amlani C. Kelly-Morland M. Fraczek K. Bailey M. Gleeson I. El-Najjar M. Streetly P. Bassett G.J.R. Cook V. Goh Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma Eur J Nucl Med Mol Imaging 2021 10.1007/s00259-020-05182-2 33469686 8241666
R. Burns S. Mulé P. Blanc-Durand M. Tofighi K. Belhadj P. Zerbib F. Le Bras L. Baranes C. Haioun E. Itti A. Luciani Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma Eur Radiol 2022 10.1007/s00330-021-08388-6 34842956
B. Jamet T. Carlier C. Bailly C. Bodet-Milin A. Monnet E. Frampas C. Touzeau P. Moreau F. Kraeber-Bodere Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results Eur Radiol 2023 10.1007/s00330-023-09593-1 37022439
Salaun P, Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bodéré-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. 2008. https://doi.org/10.3324/haematol.12654.
Fouquet G, Guidez S, Berthon C, Terriou L, Coiteux V, Macro Margaret, Decaux O, Facon T, Huglo D, Leleu X, Herbaux C, Van De Wyngaert Z, Bonnet Sarah, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. 2014. https://doi.org/10.1158/1078-0432.CCR-13-2910.
Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. 2015. https://doi.org/10.1038/bcj.2015.87.
Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bellò M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-Strauss A, Chauviè S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. 2016. https://doi.org/10.1038/leu.2015.291.
Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-term follow-up of monoclonal gammopathy of undetermined significance. 2018. https://doi.org/10.1056/NEJMoa1709974.
Rudolphi-Solero T, Triviño‐Ibáñez EM, González-Jiménez AD, Ramos-Font C, Ríos-Tamayo R, Rebollo-Aguirre AC, Sánchez-Sánchez R. Diagnostic relevance of 2‐[18F]‐FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significance. 2023. https://doi.org/10.1002/hon.3085.
Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. 2009. https://doi.org/10.1182/blood-2009-03-213280.
Michaud-Robert A, Zamagni E, Carlier T, Bailly C, Jamet B, Touzeau C, Moreau P, Kraeber-Bodere F, Nanni C, Bodet-Milin C. Glucose metabolism quantified by SUVmax on baseline FDG-PET/CT predicts survival in newly diagnosed multiple myeloma patients: combined harmonized analysis of two prospective phase iii trials. 2020. https://doi.org/10.3390/cancers12092532.
Y. Abe S. Ikeda A. Kitadate K. Narita H. Kobayashi D. Miura M. Takeuchi E. O'uchi T. O'uchi K. Matsue Low hexokinase-2 expression-associated false-negative 18 F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma Eur J Nucl Med Mol Imaging 2019 46 6 1345 1350 1:CAS:528:DC%2BC1MXntFKgsb0%3D 10.1007/s00259-019-04312-9 30903198
D. Albano G. Bosio G. Treglia R. Giubbini F. Bertagna 18F–FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma Eur J Nucl Med Mol Imaging 2018 10.1007/s00259-017-3810-5 30276438
Rama S, Suh CH, Kim KW, Durieux JC, Ramaiya NH, Tirumani SH. Comparative performance of whole-body MRI and FDG PET/CT in evaluation of multiple myeloma treatment response: systematic review and meta-analysis. 2022. https://doi.org/10.2214/AJR.21.26381.
Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. 2019. https://doi.org/10.1038/s41375-018-0329-0.
Nanni C, Kobe C, Baeßler B, Baues C, Boellaard R, Borchmann P, Buck A, Buvat I, Chapuy B, Cheson BD, Chrzan R, Cottereau A, Dührsen U, Eikenes L, Hutchings M, Jurczak W, Kraeber-Bodéré F, Lopci E, Luminari S, MacLennan S, Mikhaeel NG, Nijland M, Rodríguez-Otero P, Treglia G, Withofs N, Zamagni E, Zinzani PL, Zijlstra JM, Herrmann K, Kunikowska J. European Association of Nuclear Medicine (EANM) focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. 2023. https://doi.org/10.1016/S2352-3026(23)00030-3.
Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, Zannetti B, Rambaldi I, Brioli A, Rocchi S, Terragna C, Martello M, Marzocchi G, Borsi E, Rizzello I, Fanti S, Cavo M. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. 2015. https://doi.org/10.1158/1078-0432.CCR-15-0396.
Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, Patriarca F, Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-Milin C, Moreau P, Kraeber-Bodéré F. Standardization of 18 F-FDG–PET/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. 2021. https://doi.org/10.1200/jco.20.00386.
Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. 2018. https://doi.org/10.3324/haematol.2017.177139.
Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D'Agostino M, Belotti A, Galli M, Racca M, Zambello R, Gamberi B, Albano D, Bertamini L, Versari A, Grasso M, Sgherza N, Priola C, Fioritoni F, Patriarca F, De Cicco G, Villanova T, Pascarella A, Zucchetta P, Tacchetti P, Fanti S, Mancuso K, Barbato S, Boccadoro M, Musto P, Cavo M, Nanni C. Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. 2023. https://doi.org/10.1016/j.eclinm.2023.102017.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos M, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau J, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. 2016. https://doi.org/10.1016/S1470-2045(16)30206-6.
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. 2020. https://doi.org/10.1182/bloodadvances.2020002827.
Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, González Vélez M, Kosiorek HE, Butterfield RDJ, Kirsch IR, Mikhael JR, Stewart AK, Reeder C, Larsen J, Bergsagel PL, Fonseca R. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. 2023. https://doi.org/10.1038/s41408-023-00794-x.
K.D. Short S.V. Rajkumar D. Larson F. Buadi S. Hayman A. Dispenzieri M. Gertz S. Kumar J. Mikhael V. Roy R.A. Kyle M.Q. Lacy Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma Leukemia 2011 10.1038/leu.2011.29 21350560 3736849
S.Z. Usmani C. Heuck A. Mitchell J. Szymonifka B. Nair A. Hoering Y. Alsayed S. Waheed S. Haider A. Restrepo F. Van Rhee J. Crowley B. Barlogie Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents Haematologica 2012 10.3324/haematol.2012.065698 22733020 3487453
S. Sevcikova J. Minarik M. Stork T. Jelinek L. Pour R. Hajek Extramedullary disease in multiple myeloma - controversies and future directions Blood Rev 2019 10.1016/j.blre.2019.04.002 31005420
Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E. 18F-FDG PET/CT and MRI in the management of multiple myeloma: a comparative review. 2022. https://doi.org/10.3389/fnume.2021.808627.
L.J. Costa B.A. Derman S. Bal S. Sidana S. Chhabra R. Silbermann J.C. Ye G. Cook R.F. Cornell S.A. Holstein Q. Shi J. Omel N.S. Callander W.J. Chng V. Hungria A. Maiolino E. Stadtmauer S. Giralt M. Pasquini A.J. Jakubowiak G.J. Morgan A. Krishnan G.H. Jackson M. Mohty M.V. Mateos M.A. Dimopoulos T. Facon A. Spencer J.S. Miguel P. Hari S.Z. Usmani S. Manier P. McCarthy S. Kumar F. Gay B. Paiva International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials Leukemia 2021 10.1038/s41375-020-01012-4 34802043
Moreau P, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Karlin L, Benboubker L, Levin M, Minnema MC, Jamet B, Bodet-Milin C, Sonneveld P, Lambert J, Pei L, de Boer C, Vermeulen J, Kampfenkel T, Kraeber-Bodere F. Evaluation of the prognostic value of Positron Emission Tomography-Computed Tomography (PET-CT) at diagnosis and follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) patients treated in the phase 3 cassiopeia study: results of the cassiopet companion study. 2019. https://doi.org/10.1182/blood-2019-123143.
Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bellò M, Rambaldi I, Gallamini A, Patriarca F, Gay F, Gamberi B, Cavo M, Fanti S. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016. https://doi.org/10.1007/s00259-015-3200-9.
Kircher S, Stolzenburg A, Kortüm KM, Kircher M, Da Via M, Samnick S, Buck AK, Einsele H, Rosenwald A, Lapa C. Hexokinase-2 expression in 11 C-methionine–positive, 18 F-FDG–negative multiple myeloma. 2019. https://doi.org/10.2967/jnumed.118.217539.
Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bodéré F, Touzeau C. 2-[18F]FDG PET/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma. 2023. https://doi.org/10.1097/RLU.0000000000004588.
C. Lapa K. Luckerath U. Malzahn S. Samnick H. Einsele A.K. Buck K. Herrmann S. Knop 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation Oncotarget 2014 10.18632/oncotarget.2290 25277179 4202130
Paiva B, Puig N, Cedena M, Rosiñol L, Cordón L, Vidriales M, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz M, Martin-Ramos M, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard M, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez M, de la Rubia J, Krsnik I, Moraleda J, Palomera L, Bargay J, Van Dongen JJM, Orfao A, Mateos M, Blade J, San-Miguel JF, Lahuerta J. Measurable residual disease by next-generation flow cytometry in multiple myeloma 2020. https://doi.org/10.1200/JCO.19.01231.
G. Fouquet M. Wartski A. Dechmi L. Willems B. Deau-Fischer P. Franchi J. Descroocq P. Deschamps E. Blanc-Autran J. Clerc D. Bouscary S. Barreau N. Chapuis M. Vignon A. Cottereau Prognostic value of FDG-PET/CT parameters in patients with relapse/refractory multiple myeloma before anti-CD38 based therapy Cancers (Basel) 2021 10.3390/cancers13174323 34503133
Zukovs R, Antke C, Mamlins E, Sawicki LM, Mohring A, Lopez Y Niedenhoff D, Boquoi A, Kondakci M, Antoch G, Müller H, Fenk R, Haas R. 18F-FDG-PET/CT in relapsed multiple myeloma: are prognostic thresholds different from first-line therapy? 2022. https://doi.org/10.1186/s12880-022-00788-4.
Jamet B, Bailly C, Carlier T, Planche L, Touzeau C, Kraeber-Bodéré F, Moreau P, Bodet-Milin C. Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. 2019. https://doi.org/10.1080/10428194.2018.1459602.
Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid J, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. 11C-Methionine-PET in multiple myeloma: a combined study from two different institutions. 2017. https://doi.org/10.7150/thno.20491.
Filippi L, Frantellizzi V, Bartoletti P, Vincentis GD, Schillaci O, Evangelista L. Head-to-head comparison between FDG and 11C-methionine in multiple myeloma: a systematic review. 2023. https://doi.org/10.3390/diagnostics13122009.
Wang Y, Yee A, Bernstein Z, O'Donnell E, Raje N, Mahmood U. Carbon-11-labeled methionine PET/CT in patients with FDG-occult multiple myeloma: a prospective pilot study. 2023. https://doi.org/10.2214/AJR.22.28560.
Czyż J, Małkowski B, Jurczyszyn A, Grząśko N, Łopatto R, Olejniczak M, Czyż A, Jachalska A. 18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. 2019. https://doi.org/10.5114/wo.2019.83342.
V. Morath M. Heider M. Mittelhauser H. Rolbieski J. Stroh J. Calais M. Eiber F. Bassermann W.A. Weber Initial evaluation of [(18)F]-FACBC for PET imaging of multiple myeloma EJNMMI Res 2022 10.1186/s13550-022-00876-0 35503582 9065223
Bögelein A, Stolzenburg A, Eiring P, Lückerath K, Munawar U, Werner R, Schirbel A, Samnick S, Kortüm KM, Sauer M, Lapa C, Buck AK. CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. 2022. https://doi.org/10.1080/10428194.2022.2074986.
M. Wang J. Zhang L. Liu J. Wang C. Zhang The role of 68Ga-Pentixafor PET in multiple myeloma Clin Transl Imaging 2023 10.1007/s40336-023-00573-5
K. Philipp-Abbrederis K. Herrmann S. Knop M. Schottelius M. Eiber K. Luckerath E. Pietschmann S. Habringer C. Gerngross K. Franke M. Rudelius A. Schirbel C. Lapa K. Schwamborn S. Steidle E. Hartmann A. Rosenwald S. Kropf A.J. Beer C. Peschel H. Einsele A.K. Buck M. Schwaiger K. Gotze H. Wester U. Keller In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma EMBO Mol Med 2015 10.15252/emmm.201404698 25736399 4403048
Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester H, Knop S, Lückerath K. [68 Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18 F]FDG and laboratory values. 2017. https://doi.org/10.7150/thno.16576.
Q. Pan X. Cao Y. Luo J. Li J. Feng F. Li Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT Eur J Nucl Med Mol Imaging 2020 10.1007/s00259-019-04605-z 33336264 8113306
A.K. Buck A. Haug N. Dreher A. Lambertini T. Higuchi C. Lapa A. Weich M.G. Pomper H.J. Wester A. Zehndner A. Schirbel S. Samnick M. Hacker V. Pichler S. Hahner M. Fassnacht H. Einsele S.E. Serfling R.A. Werner Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-Pentixafor PET J Nucl Med 2022 63 11 1687 1692 1:CAS:528:DC%2BB38XjtVGis7%2FM 10.2967/jnumed.121.263693 35241482
Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, Lückerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck AK, Einsele H, Wester H, Knop S. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. 2016. https://doi.org/10.2967/jnumed.115.167361.
Chen M, Zhu W, Du J, Yang C, Han B, Zhou D, Huo L, Zhuang J. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma. 2021. https://doi.org/10.1038/s41598-021-01740-2.
Ho C, Chen S, Leung YL, Cheng T, Wong K, Cheung SK, Liang R, Chim CS. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT. 2014. https://doi.org/10.2967/jnumed.113.131169.
G.A. Ulaner N.B. Sobol J.A. O'Donoghue A.S. Kirov C.C. Riedl R. Min E. Smith L.M. Carter S.K. Lyashchenko J.S. Lewis C.O. Landgren CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging Radiology 2020 295 3 606 615 10.1148/radiol.2020192621 32255416
B. Jamet L. Morvan C. Nanni A. Michaud C. Bailly S. Chauvie P. Moreau C. Touzeau E. Zamagni C. Bodet-Milin F. Kraeber-Bodéré D. Mateus T. Carlier Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials Eur J Nucl Med Mol Imaging 2021 10.1007/s00259-020-05049-6 33006656
McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE. Assessment of total lesion glycolysis by 18F FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. 2017. https://doi.org/10.1158/1078-0432.CCR-16-0235.
Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Pre‐treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron‐emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. 2020. https://doi.org/10.1111/bjh.16633.
Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, Pane F, Salvatore M, Pace L. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. 2012. https://doi.org/10.2967/jnumed.112.106500.
R. Fonti S. Pellegrino L. Catalano F. Pane S. Del Vecchio L. Pace Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma Ann Hematol 2020 10.1007/s00277-019-03852-2 31776725
Terao T, Machida Y, Hirata K, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Tateishi U, Matsue K. Prognostic impact of metabolic heterogeneity in patients with newly diagnosed multiple myeloma using 18F-FDG PET/CT. 2021. https://doi.org/10.1097/RLU.0000000000003773.
L. Morvan T. Carlier B. Jamet C. Bailly C. Bodet-Milin P. Moreau F. Kraeber-Bodéré D. Mateus Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis Int J CARS 2020 10.1007/s11548-019-02015-y
Tagliafico AS, Cea M, Rossi F, Valdora F, Bignotti B, Succio G, Gualco S, Conte A, Dominietto A. Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: added value of a radiomics approach. 2019. https://doi.org/10.1016/j.ejrad.2019.108739.
Park H, Lee S, Lee J, Pak J, Lee K, Lee S, Jung J. Detecting multiple myeloma infiltration of the bone marrow on ct scans in patients with osteopenia: feasibility of radiomics analysis. 2022. https://doi.org/10.3390/diagnostics12040923.
Jin Z, Wang Y, Wang Y, Mao Y, Zhang F, Yu J. Application of 18F-FDG PET-CT images based radiomics in identifying vertebral multiple myeloma and bone metastases. 2022. https://doi.org/10.3389/fmed.2022.874847.
Liu J, Zeng P, Guo W, Wang C, Geng Y, Lang N, Yuan H. Prediction of high‐risk cytogenetic status in multiple myeloma based on magnetic resonance imaging: utility of radiomics and comparison of machine learning methods. 2021. https://doi.org/10.1002/jmri.27637.
E. Milara R. Alonso L. Masseing A.P. Seiffert A. Gómez-Grande E.J. Gómez J. Martínez-López P. Sánchez-González Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma Phys Eng Sci Med 2023 10.1007/s13246-023-01265-0 37155114 10209284
